Cartesian Therapeutics Inc. (RNAC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XBER 
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?
Cartesian Therapeutics, Inc. (RNAC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Cartesian Therapeutics: Uncertainty Remains
Cartesian Therapeutics' stock has rebounded sharply recently despite no significant news, driven partly by insider buying after a disappointing Phase 2b trial for Descartes-08 in myasthenia gravis. The company leverages its RNA Armory platform for mRNA cell therapies, focusing on autoimmune diseases, with Descartes-08 and Descartes-15 as its main assets. Descartes-08 showed mixed results in Phase 2b for MG, raising concerns due to endpoint changes and trial anomalies, yet plans continue for a pivotal trial in 2025.
Cartesian Therapeutics, Inc. (RNAC) Reports Q3 Loss, Lags Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $2.40 per share a year ago.
Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?
Cartesian Therapeutics, Inc. (RNAC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results
Cartesian Therapeutics, Inc.'s Descartes-08 mRNA CAR-T therapy shows promising Phase 2 results for myasthenia gravis without preconditioning chemotherapy. The company's RNA Armory platform enables precise, temporary cell modulation, reducing long-term side effects and avoiding genomic integration. Descartes-08 has received FDA Orphan and RMAT designations, with a Phase 3 trial expected to begin by the end of 2024.
Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates
Cartesian Therapeutics, Inc. (RNAC) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to loss of $2.10 per share a year ago.
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.
Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data
Cartesian Therapeutics, Inc. achieved positive results from the phase 2b study using Descartes-08 for the treatment of patients with myasthenia gravis; the End of phase 2 meeting with the FDA is expected by the end of 2024. The global market for generalized myasthenia gravis is projected to reach $7.5 billion by 2031. A soon-to-be-initiated phase 2 basket study would explore other autoimmune disorder indications for Descartes-08; The global autoimmune disease therapeutics market is expected to reach $123.5 billion by 2033.
Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study
Cartesian Therapeutics said on Tuesday that its experimental autoimmune disorder therapy met the main goal of a mid-stage trial.
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
The FDA bestows RMAT designation to Cartesian's (RNAC) lead pipeline candidate, Descartes-08, for treating myasthenia gravis. Shares rise.
